Splash Beverage Becomes Endovia Health Sciences: A New Name Over A Shell With $4K In Quarterly Revenue, Hold The Pop

Splash Beverage Becomes Endovia Health Sciences: A New Name Over A Shell With $4K In Quarterly Revenue, Hold The Pop

I am holding Splash Beverage Group out of this morning's rally. Shares were up about 8%, near $0.46, as the company finalizes its rebrand to Endovia Health Sciences, Inc. under a new EDVA ticker and reframes itself as a "diversified cannabinoid health sciences platform." Name changes are cheap, and this one is being asked to carry a heavy load: a company that produced roughly $4,000 of revenue in its most recent quarter while losing about $2.1 million. A fresh label that points investors at a hot sector is not evidence of a business, so my rating is Hold. Here is why the evidence does not support paying up for the rename.

The stock the market is bidding up

Let me start with what the price already reflects, because context matters more than the intraday move. At roughly $0.46, against the approximately 6.3 million shares outstanding after last month's reverse split, Splash Beverage trades at a market capitalization of about $3 million. To see how the shell got here, it helps to know that in July the company executed a 1-for-4 reverse stock split — a share consolidation that mechanically multiplies the price per share without changing the value of the company — specifically to stay compliant with NYSE American's minimum share-price rules. The pre-split equivalent of today's quote is around 11.5 cents. That is the price action of a stock fighting to keep its listing, not the emergence of a growth franchise.

What the company actually is right now

Strip away the branding and the operating picture is microscopic. First-quarter revenue was $4,224, down from $68,606 in the year-ago quarter. The quarter also produced a $16.2 million stockholders' deficit — the balance sheet owns far less than it owes — on top of which the company held only about $400,000 of cash. In July, management negotiated settlements on roughly $3.3 million of legacy payables for about $550,000 in cash, extinguishing the bulk of those obligations and booking a hoped-for gain of around $2.75 million. Those are the moves of a company buying itself time, and the regulatory filings carry the expected language about going concern and continued listing compliance. The business generating revenue today is a rounding error; the enterprise value lives in the story.

What the rebrand is really resting on

The new "Endovia" identity arranges three pillars: commercial pharmaceutical assets, FDA-regulated human and veterinary therapeutics, and consumer wellness products and beverages. Each deserves a separate skeptical look, because the gap between the pillars and the proof is where this trade lives.

The commercial pharma pillar is CannEpil, an investigational cannabinoid-based therapeutic for drug-resistant epilepsy that Splash licensed in July from Argent BioPharma for a 20-year exclusive term. CannEpil is the most substantive single asset in the story, but it is not a U.S.-approved product: it is available in a handful of markets such as Ireland, the U.K., Germany, and Australia through patient-access programs, while in the U.S. it stands only at the investigational stage with an FDA-assigned IND number. Paying for it was expensive relative to this balance sheet — roughly $5.5 million in new preferred equity plus a $1 million strategic investment, with a 15% net-revenue royalty owed to Argent — and the license itself must be maintained, which the company flagged as its initial focus after the rebrand. No revenue from the product has been disclosed.

The FDA-regulated development pillar is exactly what it sounds like: development, funded so far by that same $1 million commitment earmarked for FDA activities and trial preparation. No revenue there yet. And the consumer wellness and beverages pillar is the legacy business, the part of the company that just produced the $4,224 quarter. The label promises health sciences; the revenue behind it is essentially zero, and the flagship product is an unapproved drug still in development.

The scale that makes the whole thing tempting does not belong to Splash at all. In March, Splash signed a non-binding letter of intent to merge with Medterra, a private, profitable CBD operator that generated more than $52 million in revenue in fiscal 2025 from over two million customers, with founder J.P. Larsen expected to take a senior operating role. That is a real business. But it is still a letter of intent, not a definitive agreement, and closing it requires Splash to raise capital to repay Medterra's debt, reach agreement with Medterra's lenders on warrants, secure NYSE American approval, and clear shareholder votes — all on top of a balance sheet with essentially no cash to spare. The bull case leans on a CMS pilot program for CBD and a potential $30 billion market if federal reform advances. The skeptical reading is that a $3 million shell is being asked to underwrite a transaction it cannot yet afford.

Valuation: cheap for a reason

At about $3 million, this stock looks scandalously cheap — if the Medterra merger closes, even a modest stake in a profitable $52-million-revenue operator would be worth far more than today's price. That is precisely the trap. The $3 million price does not buy Medterra; it buys an unfunded, non-binding promise to try to buy Medterra, and the strain of that attempt lands on existing shareholders. Every stage of this strategy is being paid for in equity: preferred shares for CannEpil, discounted common shares for cash. One telling data point is a recent financing in which the company sold 3.85 million new shares for $607,000, a little over 16 cents apiece — and it still must raise further capital before Medterra can close. The multiple is not cheap relative to the probability-adjusted outcome, because the outcome depends on conditions that have not been met. The market is correctly discounting a contingent deal on an empty balance sheet; the 8% bump today is paying for the label, not for the close.

One mechanical note: this is also not a stock I would short. With about 1.06 million shares sold short against a float near 2.7 million, the tape is already a heavily contested, squeeze-prone one, and headline-driven pops in microcaps can run far past fundamentals. The point is not the short side; it is that the long side of this trade currently pays a narrative premium for no new operating evidence.

What would actually change my mind

The name change is not a catalyst in my framework; it is a label change. The proof points that would make the story worth revisiting are specific and observable. One: a definitive merger agreement with Medterra, with the financing disclosed. Two: NYSE American approval of the change of control. Three: any disclosed revenue from CannEpil or the wellness portfolio showing that the "health sciences" thesis is converting into paid demand. If the Medterra deal closes at sensible terms and the combined business has a funded plan, the risk/reward flips and the rating changes. Until that evidence exists, buying the pop means buying a story with no clock attached — and this is a "too early" profile, where the right posture is to wait for proof.

Takeaway

Splash Beverage is renaming itself this month, but the rename does not change the quarter behind it: roughly $4,000 of revenue, a $2.1 million loss, a $16.2 million deficit of stockholders' equity, and a going-concern warning sitting on top. The prize everyone wants — a stake in a profitable $52-million-revenue CBD operator — is still a non-binding letter of intent that this shell must find the money to fund. I am holding the stock at Hold: not shorting the pop, and not paying up for the "Endovia Health Sciences" label. The next proof point to watch is a definitive Medterra agreement with financing attached. Until one appears, the new name is worth about as much as the old one — which is to say, not yet.